

DEC. 9. 2005 4:30PM +1-212-319-5101 customer 01933

NO. 4156 P. 2

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

Appl. No. 10/600,266
Reply to Office Action of September 28, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A pharmaceutical composition comprising 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in a ratio by weight of 1:500 to 500:1 and wherein there is no thromboxane A₂ receptor antagonist.
2. **(Original)** The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable excipient.
3. **(Original)** The pharmaceutical composition of claim 1 wherein the 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.
4. **(Original)** The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the hydrochloride.

Appl. No. 10/600,266
Reply to Office Action of September 28, 2005

5. **(Original)** The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the maleate.

6. **(Withdrawn)** A method for the prevention of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

7. **(Withdrawn)** A method according to claim 6, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

8. **(Withdrawn)** A method according to claim 6 or claim 7, in which the warm-blooded animal is a human.

9. **(Withdrawn)** A method for the treatment of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-(α -cyclopropylcarbonyl-2-

Appl. No. 10/600,266
Reply to Office Action of September 28, 2005

fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

10. **(Withdrawn)** A method according to claim 9, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

11. **(Withdrawn)** A method according to claim 9 or claim 10, in which the warm-blooded animal is a human.

12. **(Withdrawn)** A method for the treatment of a patient undergoing stenting, angioplasty, and/or to prevent restenosis comprising administering a pharmaceutical composition comprising 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

13. **(Withdrawn)** A method according to claim 12, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

Appl. No. 10/600,266
Reply to Office Action of September 28, 2005

14. (Withdrawn) A method according to claim 12 or claim 13, in which the warm-blooded animal is a human.

15. (New) The pharmaceutical composition according to claim 1, consisting essentially of the 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and the aspirin, and optionally pharmaceutically acceptable excipients.

16. (New) The pharmaceutical composition of claim 15 comprising the pharmaceutically acceptable excipient.

17. (New) The pharmaceutical composition of claim 15 wherein the 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.

18. (New) The pharmaceutical composition according to claim 17, wherein the pharmaceutically acceptable salt is the hydrochloride..

19. (New) The pharmaceutical composition according to claim 17, wherein the pharmaceutically acceptable salt is the maleate.